PRE-LAUNCH WHITE PAPER:
DPYD insight is evolving – is your panel keeping up?
Download now for early access to data that could redefine your DPYD research strategy
The connection between DPYD variants and fluoropyrimidine toxicity is well recognized, but most research panels test for only four variants.
In 2024, AMP recommended testing 13 DPYD variants as essential for PGx research.
The VeriDose® DPYD Plus Panel (RUO) was developed in direct response, covering all AMP Tier 1 and 2 variants, plus four additional markers of emerging interest.
This pre-launch white paper offers a concise overview of the scientific and technical rationale behind the panel’s design, including reference allele frequencies, functional significance, and population relevance.
By completing the form, you'll get:
- Immediate access to the pre-launch white paper.
- Early delivery of the upcoming launch performance white paper, featuring data from three Beta testing sites.
This follow-up report will show how the panel performs in real-world labs, giving early adopters the insight they need to move confidently.
What will you discover in the pre-launch white paper?
- AMP’s 13 recommended variants and their functional role.
- Rationale for including 4 additional high-interest markers.
- Panel compatibility with the MassARRAY® System.
- Reference materials available for validation.
Download now and reserve early access.
Download Now
Complete the form to receive this exclusive white paper.